Related Experiment Videos
Gemfibrozil in familial and type V hyperlipidaemias. Report of 3 cases
P Varthakavi1, D P Turakhia, S Sharma
1Department of Medicine, TNM College, Bombay.
Insights
Gemfibrozil effectively lowered lipid levels in patients with familial hyperlipidaemia and Type V hyperlipidaemia, including those with insulin-dependent diabetes mellitus. This lipid-lowering agent shows promise for managing complex hyperlipidaemia cases.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Disorders
Background:
- Familial hyperlipidaemia and Type V hyperlipidaemia are genetic disorders characterized by high lipid levels.
- Insulin-dependent diabetes mellitus often coexists with dyslipidaemia, complicating patient management.
Purpose of the Study:
- To evaluate the efficacy of gemfibrozil in patients with familial hyperlipidaemia.
- To assess gemfibrozil's impact on lipid profiles in a patient with Type V hyperlipidaemia and insulin-dependent diabetes mellitus.
Main Methods:
- Gemfibrozil was administered to three patients: two with familial hyperlipidaemia and one with Type V hyperlipidaemia and insulin-dependent diabetes mellitus.
- Lipid levels, including triglycerides and cholesterol, were monitored before and during gemfibrozil therapy.
Main Results:
- Gemfibrozil demonstrated partial effectiveness in patients with familial hyperlipidaemia.
- In the patient with Type V hyperlipidaemia and insulin-dependent diabetes mellitus, gemfibrozil significantly reduced triglyceride and cholesterol levels.
Conclusions:
- Gemfibrozil therapy warrants consideration for patients diagnosed with familial hyperlipidaemia.
- A trial of gemfibrozil is recommended for individuals with Type V hyperlipidaemia, particularly when co-occurring with insulin-dependent diabetes mellitus.
Abstract:
Gemfibrozil, a lipid lowering agent, was administered to two patients with familial hyperlipidaemia and one patient with insulin dependent diabetes mellitus. It was partially effective in familial hyperlipidaemia. It dramatically reduced triglyceride and cholesterol levels in the patient with Type V hyperlipidaemia and insulin dependent diabetes mellitus. Patients with familial and Type V hyperlipidaemias should be given a trial of gemfibrozil therapy.